481 related articles for article (PubMed ID: 26614376)
21. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
Campana D; Capurso G; Partelli S; Nori F; Panzuto F; Tamburrino D; Cacciari G; Delle Fave G; Falconi M; Tomassetti P
Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1197-205. PubMed ID: 23619938
[TBL] [Abstract][Full Text] [Related]
22. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H
Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352
[No Abstract] [Full Text] [Related]
23. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.
Minczeles NS; Hofland J; de Herder WW; Brabander T
Curr Oncol Rep; 2021 Mar; 23(4):46. PubMed ID: 33721105
[TBL] [Abstract][Full Text] [Related]
24. Personalized
Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
[TBL] [Abstract][Full Text] [Related]
25. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract][Full Text] [Related]
26. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
[TBL] [Abstract][Full Text] [Related]
27. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors.
Yalchin M; Oliveira A; Theocharidou E; Pencharz D; Navalkissoor S; Quigley AM; Walker M; Caplin M; Toumpanakis C
Clin Nucl Med; 2017 Mar; 42(3):e135-e141. PubMed ID: 27922860
[TBL] [Abstract][Full Text] [Related]
28. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of
Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
[TBL] [Abstract][Full Text] [Related]
30. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.
Vinjamuri S; Gilbert TM; Banks M; McKane G; Maltby P; Poston G; Weissman H; Palmer DH; Vora J; Pritchard DM; Cuthbertson DJ
Br J Cancer; 2013 Apr; 108(7):1440-8. PubMed ID: 23492685
[TBL] [Abstract][Full Text] [Related]
31. Peptide-receptor radionuclide therapy for endocrine tumors.
van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
[TBL] [Abstract][Full Text] [Related]
32. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Sorbye H; Kong G; Grozinsky-Glasberg S
Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
[TBL] [Abstract][Full Text] [Related]
33. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
Alsadik S; Yusuf S; Al-Nahhas A
Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
[TBL] [Abstract][Full Text] [Related]
34. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
Bodei L; Kwekkeboom DJ; Kidd M; Modlin IM; Krenning EP
Semin Nucl Med; 2016 May; 46(3):225-38. PubMed ID: 27067503
[TBL] [Abstract][Full Text] [Related]
35. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
[TBL] [Abstract][Full Text] [Related]
36. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with
Kane A; Thorpe MP; Morse MA; Howard BA; Oldan JD; Zhu J; Wong TZ; Petry NA; Reiman R; Borges-Neto S
J Nucl Med; 2018 Nov; 59(11):1708-1713. PubMed ID: 29777005
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
39. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
40. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]